Indacaterol

A Novel Long-Acting β2-Agonist

Shaunta' Chamberlin, James C. Mcmillen, Sarah Eudaley, Robert S. Helmer, Andrea Franks

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Bronchodilator drugs are the foundation for the treatment of chronic obstructive pulmonary disease. The principal inhaled bronchodilator treatments used are β2-Agonists and anticholinergics, either alone or in combination. Currently available β2-Agonists are of either short duration and used multiple times/day, or of long duration, which requires twice-daily administration. Indacaterol is considered an ultra-long-Acting β2-Agonist and was recently approved for use in the United States. Its duration of action is approximately 24 hours, allowing for once-daily administration. Cough was the most commonly reported adverse effect with use of indacaterol. Cough usually occurred within 15 seconds of inhalation of the drug, lasted around 6 seconds, was not associated with bronchospasm, and did not cause discontinuation of the drug. Otherwise, the drug's safety profile was similar to that of other bronchodilators. Based on similar improvement in spirometric measurements compared with other bronchodilator drugs and the convenience of its once-daily dosing, indacaterol may be beneficial in the management of mild-to-moderate chronic obstructive pulmonary disease, either alone or in combination with anticholinergic drugs administered once/day.

Original languageEnglish (US)
Pages (from-to)456-474
Number of pages19
JournalPharmacotherapy
Volume32
Issue number5
DOIs
StatePublished - May 1 2012

Fingerprint

Bronchodilator Agents
Pharmaceutical Preparations
Cholinergic Antagonists
Cough
Chronic Obstructive Pulmonary Disease
Inhalation Administration
Bronchial Spasm
indacaterol
Safety
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Indacaterol : A Novel Long-Acting β2-Agonist. / Chamberlin, Shaunta'; Mcmillen, James C.; Eudaley, Sarah; Helmer, Robert S.; Franks, Andrea.

In: Pharmacotherapy, Vol. 32, No. 5, 01.05.2012, p. 456-474.

Research output: Contribution to journalReview article

Chamberlin, Shaunta' ; Mcmillen, James C. ; Eudaley, Sarah ; Helmer, Robert S. ; Franks, Andrea. / Indacaterol : A Novel Long-Acting β2-Agonist. In: Pharmacotherapy. 2012 ; Vol. 32, No. 5. pp. 456-474.
@article{241b70f81e9846b480672282bb053a03,
title = "Indacaterol: A Novel Long-Acting β2-Agonist",
abstract = "Bronchodilator drugs are the foundation for the treatment of chronic obstructive pulmonary disease. The principal inhaled bronchodilator treatments used are β2-Agonists and anticholinergics, either alone or in combination. Currently available β2-Agonists are of either short duration and used multiple times/day, or of long duration, which requires twice-daily administration. Indacaterol is considered an ultra-long-Acting β2-Agonist and was recently approved for use in the United States. Its duration of action is approximately 24 hours, allowing for once-daily administration. Cough was the most commonly reported adverse effect with use of indacaterol. Cough usually occurred within 15 seconds of inhalation of the drug, lasted around 6 seconds, was not associated with bronchospasm, and did not cause discontinuation of the drug. Otherwise, the drug's safety profile was similar to that of other bronchodilators. Based on similar improvement in spirometric measurements compared with other bronchodilator drugs and the convenience of its once-daily dosing, indacaterol may be beneficial in the management of mild-to-moderate chronic obstructive pulmonary disease, either alone or in combination with anticholinergic drugs administered once/day.",
author = "Shaunta' Chamberlin and Mcmillen, {James C.} and Sarah Eudaley and Helmer, {Robert S.} and Andrea Franks",
year = "2012",
month = "5",
day = "1",
doi = "10.1002/j.1875-9114.2012.01025.x",
language = "English (US)",
volume = "32",
pages = "456--474",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "5",

}

TY - JOUR

T1 - Indacaterol

T2 - A Novel Long-Acting β2-Agonist

AU - Chamberlin, Shaunta'

AU - Mcmillen, James C.

AU - Eudaley, Sarah

AU - Helmer, Robert S.

AU - Franks, Andrea

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Bronchodilator drugs are the foundation for the treatment of chronic obstructive pulmonary disease. The principal inhaled bronchodilator treatments used are β2-Agonists and anticholinergics, either alone or in combination. Currently available β2-Agonists are of either short duration and used multiple times/day, or of long duration, which requires twice-daily administration. Indacaterol is considered an ultra-long-Acting β2-Agonist and was recently approved for use in the United States. Its duration of action is approximately 24 hours, allowing for once-daily administration. Cough was the most commonly reported adverse effect with use of indacaterol. Cough usually occurred within 15 seconds of inhalation of the drug, lasted around 6 seconds, was not associated with bronchospasm, and did not cause discontinuation of the drug. Otherwise, the drug's safety profile was similar to that of other bronchodilators. Based on similar improvement in spirometric measurements compared with other bronchodilator drugs and the convenience of its once-daily dosing, indacaterol may be beneficial in the management of mild-to-moderate chronic obstructive pulmonary disease, either alone or in combination with anticholinergic drugs administered once/day.

AB - Bronchodilator drugs are the foundation for the treatment of chronic obstructive pulmonary disease. The principal inhaled bronchodilator treatments used are β2-Agonists and anticholinergics, either alone or in combination. Currently available β2-Agonists are of either short duration and used multiple times/day, or of long duration, which requires twice-daily administration. Indacaterol is considered an ultra-long-Acting β2-Agonist and was recently approved for use in the United States. Its duration of action is approximately 24 hours, allowing for once-daily administration. Cough was the most commonly reported adverse effect with use of indacaterol. Cough usually occurred within 15 seconds of inhalation of the drug, lasted around 6 seconds, was not associated with bronchospasm, and did not cause discontinuation of the drug. Otherwise, the drug's safety profile was similar to that of other bronchodilators. Based on similar improvement in spirometric measurements compared with other bronchodilator drugs and the convenience of its once-daily dosing, indacaterol may be beneficial in the management of mild-to-moderate chronic obstructive pulmonary disease, either alone or in combination with anticholinergic drugs administered once/day.

UR - http://www.scopus.com/inward/record.url?scp=84864580298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864580298&partnerID=8YFLogxK

U2 - 10.1002/j.1875-9114.2012.01025.x

DO - 10.1002/j.1875-9114.2012.01025.x

M3 - Review article

VL - 32

SP - 456

EP - 474

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 5

ER -